{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:52:45Z","timestamp":1786981965594,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"This study was funded by Eli Lilly and Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11523-023-00975-5","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T05:02:05Z","timestamp":1686978125000},"page":"505-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study"],"prefix":"10.1007","volume":"18","author":[{"given":"Chao-Hua","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Chih","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Chun","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kuei-Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hua","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"key":"975_CR1","unstructured":"World Health Organization. Cancer. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer. Accessed 11 May 2022."},{"key":"975_CR2","unstructured":"Taiwan Ministry of Health and Welfare. Cause of death statistics. 2019. https:\/\/www.mohw.gov.tw\/cp-4650-50697-2.html. Accessed 11 May 2022."},{"issue":"4","key":"975_CR3","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","volume":"16","author":"MG Oser","year":"2015","unstructured":"Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(14)71180-5.","journal-title":"Lancet Oncol"},{"issue":"2","key":"975_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3978\/j.issn.2218-6751.2015.01.01","volume":"4","author":"CN Prabhakar","year":"2015","unstructured":"Prabhakar CN. Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Canc Res. 2015;4(2):110. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2015.01.01.","journal-title":"Transl Lung Canc Res"},{"issue":"5","key":"975_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339\u201346. https:\/\/doi.org\/10.1093\/jnci\/dji055.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl. 1","key":"975_CR6","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","volume":"29","author":"WH Hsu","year":"2018","unstructured":"Hsu WH, Yang JH, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29(Suppl. 1):i3-9. https:\/\/doi.org\/10.1093\/annonc\/mdx702.","journal-title":"Ann Oncol"},{"issue":"3","key":"975_CR7","doi-asserted-by":"publisher","first-page":"e0120852","DOI":"10.1371\/journal.pone.0120852","volume":"10","author":"KH Hsu","year":"2015","unstructured":"Hsu KH, Ho CC, Hsia TC, Tseng JS, Su KY, Wu MF, et al. Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. PLoS\u00a0One. 2015;10(3):e0120852. https:\/\/doi.org\/10.1371\/journal.pone.0120852.","journal-title":"PLoS\u00a0One"},{"issue":"Suppl. 1","key":"975_CR8","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"A Gazdar","year":"2009","unstructured":"Gazdar A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl. 1):S24-31. https:\/\/doi.org\/10.1038\/onc.2009.198.","journal-title":"Oncogene"},{"issue":"Supp. 4","key":"975_CR9","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat ST, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supp. 4):iv192-237. https:\/\/doi.org\/10.1093\/annonc\/mdy275.","journal-title":"Ann Oncol"},{"issue":"1","key":"975_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00228-015-1966-0","volume":"72","author":"M Sheng","year":"2016","unstructured":"Sheng M, Wang F, Zhao Y, Li S, Wang X, Shou T, et al. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis. Eur J Clin Pharmacol. 2016;72(1):1\u201311. https:\/\/doi.org\/10.1007\/s00228-015-1966-0.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"975_CR11","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"AH Yu","year":"2013","unstructured":"Yu AH, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Canc Res. 2013;19(8):2240\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2246.","journal-title":"Clin Canc Res"},{"issue":"1","key":"975_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"SG Wu","year":"2018","unstructured":"Wu SG, Shih JY. Management of acquired resistance to EGFR TKI\u2013targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):1\u201314. https:\/\/doi.org\/10.1186\/s12943-018-0777-1.","journal-title":"Mol Cancer"},{"issue":"18","key":"975_CR13","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.3390\/cancers13184705","volume":"13","author":"O Rodak","year":"2021","unstructured":"Rodak O, Peris-D\u00edaz MD, Olbromski M, Podhorska-Oko\u0142\u00f3w M, Dzi\u0119giel P. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. Cancers. 2021;13(18):4705. https:\/\/doi.org\/10.3390\/cancers13184705.","journal-title":"Cancers"},{"key":"975_CR14","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.3389\/fphar.2021.746707","volume":"12","author":"Q Cui","year":"2022","unstructured":"Cui Q, Hu Y, Cui Q, Wu D, Mao Y, Ma D, et al. Osimertinib rechallenge with bevacizumab vs chemotherapy plus bevacizumab in EGFR-mutant NSCLC patients with osimertinib resistance. Front Pharmacol. 2022;12:3724. https:\/\/doi.org\/10.3389\/fphar.2021.746707.","journal-title":"Front Pharmacol"},{"issue":"10","key":"975_CR15","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3390\/cells11101694","volume":"11","author":"C Osude","year":"2022","unstructured":"Osude C, Lin L, Patel M, Eckburg A, Berei J, Kuckovic A, et al. Mediating EGFR-TKI resistance by VEGF\/VEGFR autocrine pathway in non-small cell lung cancer. Cells. 2022;11(10):1694. https:\/\/doi.org\/10.3390\/cells11101694.","journal-title":"Cells"},{"issue":"2","key":"975_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","volume":"16","author":"X Le","year":"2021","unstructured":"Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16(2):205\u201315. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.006.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"975_CR17","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","volume":"15","author":"GN Naumov","year":"2009","unstructured":"Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clinl Canc Res. 2009;15(10):3484\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2904.","journal-title":"Clinl Canc Res"},{"issue":"11","key":"975_CR18","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","volume":"15","author":"T Seto","year":"2014","unstructured":"Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236\u201344. https:\/\/doi.org\/10.1016\/S1470-2045(14)70381-X.","journal-title":"Lancet Oncol"},{"issue":"5","key":"975_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(19)30035-X.","journal-title":"Lancet Oncol"},{"issue":"12","key":"975_CR20","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(19)30634-5.","journal-title":"Lancet Oncol"},{"key":"975_CR21","unstructured":"Chiu C, Lin M, Wei Y, Chang G, Su W, Hsia T, et al. Efficacy and safety of ramucirumab (RAM) plus erlotinib (ERL) in Taiwanese patients with untreated, EGFR-mutated metastatic non-small-cell lung cancer (mnsclc) participating in the global phase 3 RELAY study. In Presented at the Taiwan Society of Pulmonary and Critical Care Medicine\u20142020 Annual Meeting; Taipei, Taiwan. Poster PA40."},{"issue":"22","key":"975_CR22","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","volume":"18","author":"S Dogan","year":"2012","unstructured":"Dogan S, Shen R, Ang DC, Johnson ML, D\u2019Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Canc Res. 2012;18(22):6169\u201377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3265.","journal-title":"Clin Canc Res."},{"issue":"1","key":"975_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methods. 2013;13(1):1\u201315. https:\/\/doi.org\/10.1186\/1471-2288-13-152.","journal-title":"BMC Med Res Methods"},{"issue":"9","key":"975_CR24","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer novel mutant-selective EGFR inhibitor overcomes drug resistance. Canc Discov. 2014;4(9):1046\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0337.","journal-title":"Canc Discov"},{"issue":"2","key":"975_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New Eng J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"New Eng J Med"},{"issue":"4","key":"975_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009.","journal-title":"Ann Oncol"},{"issue":"5","key":"975_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497\u2013530. https:\/\/doi.org\/10.6004\/jnccn.2022.0025.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"975_CR28","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1200\/JCO.22.02782","volume":"41","author":"IA Jaiyesimi","year":"2023","unstructured":"Jaiyesimi IA, Owen DH, Ismaila N, Blanchard E, Celano P, Florez N, et al. Therapy for stage IV non\u2013small-cell lung cancer with driver alterations: ASCO living guideline, version 20223. J Clin Oncol. 2023;41(11):e31\u201341. https:\/\/doi.org\/10.1200\/JCO.22.02782.","journal-title":"J Clin Oncol"},{"key":"975_CR29","doi-asserted-by":"publisher","first-page":"v914","DOI":"10.1056\/NEJMoa1913662","volume":"30","author":"SS Ramalingam","year":"2019","unstructured":"Ramalingam SS, Gray JE, Ohe Y, Cho BC, Vansteenkiste J, Zhou C, et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis. Ann Oncol. 2019;30:v914\u20135. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"Ann Oncol"},{"issue":"12","key":"975_CR30","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1111\/cas.14655","volume":"111","author":"M Nishio","year":"2020","unstructured":"Nishio M, Seto T, Reck M, Garon EB, Chiu CH, Yoh K, et al. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY. Cancer Sci. 2020;111(12):4510\u201325. https:\/\/doi.org\/10.1111\/cas.14655.","journal-title":"Cancer Sci"},{"issue":"6","key":"975_CR31","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.jtocrr.2021.100171","volume":"2","author":"K Nishio","year":"2021","unstructured":"Nishio K, Seto T, Nishio M, Reck M, Garon EB, Sakai K, et al. Ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated metastatic EGFR-mutated NSCLC: RELAY Japanese Subset. JTO Clin Res Rep. 2021;2(6):100171. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100171.","journal-title":"JTO Clin Res Rep."},{"issue":"9","key":"975_CR32","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","volume":"39","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Xu CR, Cheng Y, Liu YP, Chen GY, Cui JW, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study. Canc Cell. 2021;39(9):1279\u201391. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.005.","journal-title":"Canc Cell"},{"key":"975_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","volume":"151","author":"N Yamamoto","year":"2021","unstructured":"Yamamoto N, Seto T, Nishio M, Goto K, Okamoto I, Yamanaka T, et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study. Lung Cancer. 2021;151:20\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.020.","journal-title":"Lung Cancer"},{"key":"975_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.critrevonc.2018.12.001","volume":"134","author":"J Li","year":"2019","unstructured":"Li J, Gu J. Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2019;134:31\u20138. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.12.001.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"975_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000371821","volume":"1","author":"G Fabbrocini","year":"2015","unstructured":"Fabbrocini G, Panariello L, Caro G, Cacciapuoti S. Acneiform rash induced by EGFR inhibitors: review of the literature and new insights. Skin Appendage Disord. 2015;1(1):31\u20137. https:\/\/doi.org\/10.1159\/000371821.","journal-title":"Skin Appendage Disord"},{"issue":"2","key":"975_CR36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","volume":"71","author":"AK Pandey","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71(2):e1-8. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10271.","journal-title":"Hypertension"},{"issue":"Suppl 3","key":"975_CR37","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.21037\/tlcr.2019.05.02","volume":"8","author":"Y He","year":"2019","unstructured":"He Y, Zhou C. Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management. Transl Lung Canc Res. 2019;8(Suppl 3):S318. https:\/\/doi.org\/10.21037\/tlcr.2019.05.02.","journal-title":"Transl Lung Canc Res"},{"issue":"16","key":"975_CR38","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24(16):2549\u201356. https:\/\/doi.org\/10.1200\/JCO.2005.04.9866.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00975-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00975-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00975-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T06:20:12Z","timestamp":1689229212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00975-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00975-5","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]},"assertion":[{"value":"6 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Chao-Hua Chiu has received consulting fees or honorarium from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Company, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche, Shionogi and Takeda. Gee-Chen Chang, Meng-Chih Lin, Jian Su, Wu-Chou Su and Yu-Feng Wei have no conflicts to declare. Te-Chun Hsia has received payment for lectures including service on speakers bureaus from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Roche, Takeda, Merck Sharp & Dohme, Merck KGaA, Bristol Myers Squibb and Amgen. Jin-Yuan Shih has received grants from Roche and Genconn Biotech; consulting fees or honorarium from ACT Genomics, Amgen, Genconn Biotech, AstraZeneca, Roche, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Novartis, Merck Sharp & Dohme, Chugai Pharmaceutical, Takeda, CStone Pharmaceuticals, Janssen, TTY Biopharm, Orient EuroPharma, Mundipharma, Ono Pharmaceutical and Bristol Myers Squibb; and travel support from AstraZeneca, Roche, Boehringer Ingelheim and Chugai Pharmaceutical. Anne Kuei-Fang Wang, Min-Hua Jen and Tarun Puri are employees of Eli Lilly and Company with stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors contributed to the study conception\/design or acquisition, analysis and interpretation of the data. All authors critically revised the manuscript for important intellectual content and have read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The protocol and amendments were approved by the ethics committees of all participating centers.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients prior to participating in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Eli Lilly provides access to all individual participant data collected during the trial, after anonymisation, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the USA and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once they are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms will be provided in a secure data sharing environment for up to 2 years per proposal. For details on submitting a request, see the Vivli website.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}